对于高血压的脏缩:当前的景观和未来的方向
Brian Fulton1, Jay Giri1,2, Florian Rader3
1Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Heart international
|July 15, 2024
概括
使用射频或超声波来切除神经的损疗法,现在已被FDA批准用于不受控制的高血压. 这种辅助治疗为管理高血压和降低心血管风险提供了新的选择.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 医疗器械 医疗器械
背景情况:
- 高血压影响了47%的美国成年人,超过40%的血压不受控制,这对心血管疾病发病率和死亡率作出了重大贡献.
- 脏缺血已经成为一个有前途的辅助疗法,最近的随机对照试验证明了它的安全性和有效性.
研究的目的:
- 审查脏缩 (RDN) 作为高血压的辅助治疗的安全性和有效性.
- 讨论最近美国食品和药物管理局 (FDA) 对RDN设备的批准的影响.
- 探索RDN技术的未来前景,包括应用和报销.
主要方法:
- 对多项安慰剂受控随机研究的审查,评估RDN.
- 分析支持RDN在降低血压方面的功效的数据.
- 检查射频和超声波RDN设备的作用机制.
主要成果:
- 多项研究表明,RDN作为高血压的辅助治疗的安全性和有效性.
- 两种RDN设备的FDA批准标志着该技术的一个重要里程碑.
- 通过切除周脉交感神经,RDN有效降低血压.
结论:
- 脏缩代表了控制不良的高血压管理的重大进展.
- FDA批准后的时代为RDN实施带来了机遇和挑战.
- 需要进一步的研究和政策制定,以优化RDN在心血管保健中的作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antihypertensive Drugs: Direct Renin Inhibitors
546
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
546
Neural Regulation of Blood Pressure
2.7K
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
2.7K
Hypertension and Regulation of Blood Pressure
2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
600
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
600
Antihypertensive Drugs: Vasodilators
502
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
502


